Business
Neuro-Biotech Corp. (MRES.PK) Performs Reverse Merger With the Institute of Biomedical Research
Neuro-Biotech Corp. (MRES.PK) Performs Reverse Merger With the Institute of Biomedical Research.
About this update from Institute Of Biomedical Research Corp.
[{"type":"text","content":"\n \n \n Neuro-Biotech Corp. (MRES.PK) Performs Reverse Merger With the Institute of Biomedical Research\n \n \nNeuro-Biotech Corp. (MRES.PK) Performs Reverse Merger With the Institute of Biomedical Research\n \n PODGORICA, MONTENEGRO--(Marketwired - Feb 10, 2014) - Neuro-Biotech Corp. (OTC Pink: MRES) announced today that it completed the acquisition of the Institute of Biomedical Research (the \"Institute\"), which is now a wholly-owned subsidiary of MRES. The Company's official website is now: www.institutebmr.com. \n The Institute of Biomedical Research is an ambitious biomedical business venture whose activities extend from highly diversified scientific research and sophisticated services research and development, quality control and standardisation of pharmaceuticals, (cosmetics and food products) up to major long term biomedical and environmental research projects, as well as the development of new diagnostic technologies and innovative experimental medical treatments. Regulatory certification of new drugs and biomedical products also constitutes important business activities of the Institute. The Institute is essential for the development of Montenegro within the regional and European environment. \n Dr. Drasko Pekovic, the new President of MRES, said, \"This transaction is a large step forward in the development of the Institute, and we envision that it will be instrumental in our forward progress.\" \n The transaction was achieved by the acquisition by MRES of all of the stock of the Institute in exchange for newly issued stock of MRES. The shareholders of the Institute, Dr. Drasko Pekovic and the Government of Montenegro, now hold majority control of MRES. \n Legal Notice Regarding Forward-Looking Statements\n No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Neuro-Biotech Corp. (the \"Company\" or \"MRES\") believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve as...